Xiaoya Wei

Ms. Xiaoya Wei

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 October 2023 in Microbiology Spectrum
Verified
Journal Article
Open access
XWXiaoya Wei
Xiaoya Wei
JGJiacong Gao
Jiacong Gao
CXCongjuan Xu
Congjuan Xu
XPXiaolei Pan
Xiaolei Pan
YJYongxin Jin
Yongxin Jin
WWWeihui Wu
Weihui Wu
Pseudomonas aeruginosa is a ubiquitous opportunistic pathogen that can cause a variety of acute and chronic infections. The bacterium is highly resistant to numerous antibiotics. Murepavadin is a peptidomimetic antibiotic that blocks the function of P. aeruginosa lipopolysaccharide (LPS) transport protein D (LptD), thus inhibiting the insertion of LPS into the outer membrane. In this study, we demonstrated that sublethal concentrations of murepavadin enhance the bacterial outer membrane permeability. Proteomic analyses revealed the alteration of protein composition in bacterial inner and outer membranes following murepavadin treatment. The antisigma factor MucA was upregulated by murepavadin. In addition, the expression of the sigma E factor gene algU and the alginate synthesis gene algD was induced by murepavadin. Deletion of the algU gene reduces bacterial survival following murepavadin treatment, indicating a role of the envelope stress response in bacterial tolerance. We further demonstrated that murepavadin enhances the bactericidal activities of β-lactam antibiotics by promoting drug influx across the outer membrane. In a mouse model of acute pneumonia, the murepavadin–ceftazidime/avibactam combination showed synergistic therapeutic effect against P. aeruginosa infection. In addition, the combination of murepavadin with ceftazidime/avibactam slowed down the resistance development. In conclusion, our results reveal the response mechanism of P. aeruginosa to murepavadin and provide a promising antibiotic combination for the treatment of P. aeruginosa infections. Importance: The ever increasing resistance of bacteria to antibiotics poses a serious threat to global public health. Novel antibiotics and treatment strategies are urgently needed. Murepavadin is a novel antibiotic that blocks the assembly of lipopolysaccharide (LPS) into the Pseudomonas aeruginosa outer membrane by inhibiting LPS transport protein D (LptD). Here, we demonstrated that murepavadin impairs bacterial outer membrane integrity, which induces the envelope stress response. We further found that the impaired outer membrane integrity increases the influx of β-lactam antibiotics, resulting in enhanced bactericidal effects. In addition, the combination of murepavadin and a β-lactam/β-lactamase inhibitor mixture (ceftazidime/avibactam) slowed down the resistance development of P. aeruginosa . Overall, this study demonstrates the bacterial response to murepavadin and provides a new combination strategy for effective treatment.

26 August 2024 in Antibiotics
Verified
Journal Article
Open access
PDF file
XWXiaoya Wei
Xiaoya Wei
DZDandan Zhou
Dandan Zhou
CXCongjuan Xu
Congjuan Xu
PCPing Chen
Ping Chen
SCShuiping Chen
Shuiping Chen
WWWeihui Wu
Weihui Wu
Pseudomonas aeruginosa is a multidrug-resistant Gram-negative pathogen and one of the leading causes of ventilator-associated pneumonia and infections in patients with chronic obstructive pulmonary disease and cystic fibrosis. Murepavadin is a peptidomimetic that specifically targets outer-membrane lipopolysaccharide transport protein LptD of P. aeruginosa. In this study, we find that murepavadin enhances the bactericidal efficacy of ciprofloxacin. We further demonstrate that murepavadin increases intracellular accumulation of ciprofloxacin by suppressing drug efflux. In addition, the murepavadin–ciprofloxacin combination exhibits a synergistic bactericidal effect in an acute murine pneumonia model. In conclusion, our results identify an effective drug combination for the treatment of P. aeruginosa infections.

3 April 2024 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
XWXiaoya Wei
Xiaoya Wei
JGJiacong Gao
Jiacong Gao
DZDandan Zhou
Dandan Zhou
CXCongjuan Xu
Congjuan Xu
PCPing Chen
Ping Chen
WWWeihui Wu
Weihui Wu
Murepavadin is a peptidomimetic that specifically targets the lipopolysaccharide transport protein LptD of Pseudomonas aeruginosa . Here, we found that murepavadin enhances the bactericidal efficacies of tobramycin and amikacin. We further demonstrated that murepavadin enhances bacterial respiration activity and subsequent membrane potential, which promotes intracellular uptake of aminoglycoside antibiotics. In addition, the murepavadin-amikacin combination displayed a synergistic bactericidal effect in a murine pneumonia model.

6 October 2026 in Microbiology Spectrum
Verified
Journal Article
Open access
XWXiaoya Wei
Xiaoya Wei
ZYZhonghui Yang
Zhonghui Yang
YZYujie Zhang
Yujie Zhang
XXXin Xia
Xin Xia
ZCZhihui Cheng
Zhihui Cheng
WWWeihui Wu
Weihui Wu
Dequalinium chloride is a dicationic amphiphilic quaternary ammonium compound that is used as an anti-infective drug. Here, we found that it potentiates bactericidal efficacies of aminoglycoside antibiotics against Pseudomonas aeruginosa . Dequalinium chloride increases respiratory activity and bacterial membrane potential, thereby promoting intracellular uptake of aminoglycosides. Furthermore, the dequalinium chloride–amikacin combination demonstrated a synergistic bactericidal effect in a murine acute pneumonia model, indicating its therapeutic potential. IMPORTANCE: Antimicrobial resistance (AMR) poses a severe global health threat. Novel antibiotics and therapeutic strategies are urgently needed. This study revealed that dequalinium chloride (DC) synergizes with aminoglycosides against planktonic and biofilm-associated P. aeruginosa , which is an important pathogen. Mechanistic study reveals that DC enhances bacterial respiration and membrane potential to promote aminoglycosides uptake. The DC–amikacin combination is effective in a murine pneumonia model. These findings provide a promising therapeutic strategy for combating P. aeruginosa infections.

25 August 2026 in Microorganisms
Verified
Journal Article
Open access
PDF file
MWMengyao Wang
Mengyao Wang
YZYuHong Zhou
YuHong Zhou
MLMengxiao Li
Mengxiao Li
SQShanhua Qin
Shanhua Qin
ZQZiyue Qi
Ziyue Qi
ZCZhihui Cheng
Zhihui Cheng
Ehrlichia chaffeensis is an obligate intracellular bacterium that proliferates within monocytes or macrophages and causes human monocytic ehrlichiosis (HME), an emerging life-threatening zoonosis. Doxycycline is the choice of treatment for HME, yet it has prominent side effects. Host cells lack the lysine biosynthetic pathway; thus, the enzymes in this pathway are essential for bacterial growth and recognized as potential targets for the development of novel antibiotics. Here, we demonstrated that inhibitors targeting DapE, which is a key enzyme in the lysine biosynthetic pathway, especially disulfiram, effectively inhibit E. chaffeensis infection and intracellular growth. Through complementation experiments and peptide nucleic acid-mediated dapE knockdown, we showed that DapE in E. chaffeensis is functional and essential for bacterial intracellular growth. Using purified recombinant protein, we found that DapE induces IL-8 expression in host cells. Finally, we identified that NtrX, the response regulator of the two-component system NtrY/NtrX, regulates dapE expression using an electrophoretic mobility shift assay and a reporter assay. Our findings deepen the understanding of E. chaffeensis pathogenesis as well as illustrate that DapE in E. chaffeensis is a potential therapeutic target for the development of novel HME treatments.